Zentalis Pharmaceuticals, Inc.
ZNTLNext catalyst
azenosertib
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Get an email about ZNTL's next catalysts
Track Zentalis Pharmaceuticals (ZNTL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
ZNTL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.58 | FQ end Sep/2026 | Call: tbd
azenosertib Phase 2 Est. Readout (DENALI)
Primary completion for azenosertib trial (NCT05128825) in High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
SourceAzenosertib Phase 2 Est. Readout
Estimated primary completion for Azenosertib trial (NCT06369155) in Uterine Serous Carcinoma. Topline data typically follows completion by weeks to months.
SourceHow ZNTL's past catalysts played out
Market Overview
Stock performance and key metrics
azenosertib
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ZN-d5
Amyloidosis
Niraparib
Ovarian Cancer
ZN-c3
Uterine Serous Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
azenosertib | Phase 3 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | - | - |
ZN-d5 | Phase 2 | Amyloidosis | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
ZN-c3 | Phase 2 | Uterine Serous Carcinoma | - | - |
Ovarian Cancer
2 drugs in this indication
Amyloidosis
1 drug in this indication
Uterine Serous Carcinoma
1 drug in this indication
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Zentalis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Zentalis Pharmaceuticals, Inc.'s (ZNTL) pipeline across Phase 3, Phase 2. Its lead program is azenosertib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zentalis Pharmaceuticals, Inc.'s next FDA catalyst?→
Zentalis Pharmaceuticals, Inc.'s (ZNTL) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZNTL biotech catalysts?→
Add ZNTL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zentalis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.